MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

MDT

97.17

+2.33%↑

VEEV

295.69

+0.08%↑

A

141.95

+2.63%↑

HQY

90.19

-0.24%↓

PHR.US

23.94

+5.88%↑

Search

Krystal Biotech Inc

Aperta

SettoreSettore sanitario

180.22 0.15

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

178.69

Massimo

182.1

Metriche Chiave

By Trading Economics

Entrata

2.6M

38M

Vendite

7.9M

96M

P/E

Media del settore

34.122

35.739

Margine di Profitto

39.914

Dipendenti

275

EBITDA

1.5M

39M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+12.4% upside

Dividendi

By Dow Jones

Utili prossimi

3 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.2B

5.1B

Apertura precedente

180.07

Chiusura precedente

180.22

Notizie sul Sentiment di mercato

By Acuity

50%

50%

149 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Krystal Biotech Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 ott 2025, 23:30 UTC

Azioni calde

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 ott 2025, 21:21 UTC

Utili

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 ott 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 ott 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 ott 2025, 23:39 UTC

Discorsi di Mercato

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 ott 2025, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 ott 2025, 23:00 UTC

Discorsi di Mercato

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 ott 2025, 22:54 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 ott 2025, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 ott 2025, 21:17 UTC

Acquisizioni, Fusioni, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 ott 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Energy & Utilities Roundup: Market Talk

2 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

2 ott 2025, 20:49 UTC

Acquisizioni, Fusioni, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 ott 2025, 20:00 UTC

Acquisizioni, Fusioni, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 ott 2025, 19:20 UTC

Discorsi di Mercato

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 ott 2025, 19:10 UTC

Discorsi di Mercato

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 ott 2025, 19:04 UTC

Discorsi di Mercato

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 ott 2025, 18:46 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 ott 2025, 18:45 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 ott 2025, 18:44 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 ott 2025, 18:43 UTC

Acquisizioni, Fusioni, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Confronto tra pari

Modifica del prezzo

Krystal Biotech Inc Previsione

Obiettivo di Prezzo

By TipRanks

12.4% in crescita

Previsioni per 12 mesi

Media 201.88 USD  12.4%

Alto 240 USD

Basso 166 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Krystal Biotech Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

8

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

133.221 / 169.73Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

149 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
help-icon Live chat